Last checked at 3 Dec 2010 07:00
Press Release | 03 December 2010 |
Syntopix Group plc
("Syntopix" or "the Company")
Grant of share options to Directors
Syntopix Group plc (AIM: SYN), the speciality research group focused on topical antimicrobial innovations for products in the medicinal and consumer healthcare markets announces that on 2 December 2010, a total of 123,790 options over the Company's ordinary shares were granted to Directors pursuant to the Syntopix Executive Share Option Scheme (the "ESO Scheme"). In addition, a further 38,095 options over the Company's ordinary shares were granted to IP Group plc ("IP Group") in respect of the provision by IP Group of the services of Mike Townend to serve as a non-executive Director of Syntopix. These options were granted in place of Directors' fees waived by IP Group. Mr Townend has no beneficial interest in the options granted.
The options were granted for nil consideration with an exercise price of 52.5 pence per share and are exercisable after 12 months from the date of grant. There are no performance conditions attached to these share options other than the Directors concerned must be still in position in order for the options to vest. The options have been granted in exchange for the waiver of Directors' fees for a further period of 12 months by each of the Directors who have been granted options.
As a result of these options being granted, the interests of these Directors in options are as follows:
Name of Director | Options granted | Total options | ESO scheme |
Tom Bannatyne | 47,600 | 47,600 | 47,600 |
Gwyn Humphreys | 38,095 | 64,762 | 64,762 |
Darren Bamforth | 38,095 | 114,627 | 114,627 |
Save for the above, the Directors beneficial interests remain unchanged and as previously announced.
- Ends -
For further information, please contact:
Syntopix Group plc | |
Dr Stephen Jones, Chief Executive Officer | +44 (0)845 125 9204 |
www.syntopix.com |
Zeus Capital Ltd | |
Alex Clarkson | Tel: +44(0)161 831 1512 |
www.zeuscapital.co.uk |
Media enquiries:
Abchurch Communications | |
Sarah Hollins / Simone Elviss / Claire Dickinson | Tel: +44 (0) 20 7398 7728 |
simone.elviss@abchurch-group.com | www.abchurch-group.com |
Notes to editors
Syntopix is a specialised research and development company, focusing on topical antimicrobial innovations for the cosmetic, consumer healthcare and pharmaceutical markets. The Group was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the world's leading experts in skin microbiology.
Syntopix combines scientific excellence with an understanding of consumer need to identify and develop innovative compounds which have clinical efficacy and proven benefits for the treatment of acne, gingivitis and body odour.
The Group has a robust research pipeline, with a growing library of over 2,700 compounds (with established safety profiles) profiled both individually and in combination for their antimicrobial activity. The Group, which currently has 12 granted UK patent applications, raised £2 million in March 2010 to undertake clinical studies with its lead compounds and to further develop the pipeline.
The Group's development activities centre on several lead compounds which have multiple potential uses across a number of large consumer healthcare markets including skincare, body odour and oral health. The lead compound, SYN1113, a naturally derived cosmetic ingredient and lead acne treatment candidate, has been shown in the laboratory to be as potent as the market leader (benzoyl peroxide) and will be trialled in volunteers soon. The Group is actively seeking to out-licence its technologies to commercial partners.
Syntopix's shareholders include IP Group plc, The Wellcome Trust Limited, The University of Leeds and Ridings Early Growth Investment Company Limited. Syntopix joined the AIM market of the London Stock Exchange in March 2006. For more information, please visit our website at www.syntopix.com.
- Ends -